Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette-Guerin therapy in patients with non-muscle invasive bladder cancer.

ABSTRACT:

Background

Metabolomic research and metabolomics-based biomarkers predicting treatment outcomes in bladder cancer remain limited.

Objective

We explored the serum metabolites potentially associated with the risk of recurrence after intravesical Bacillus Calmette-Guérin (BCG) therapy.

Methods

Two independent cohorts, a discovery cohort (n = 23) and a validation cohort (n = 40), were included in this study. Blood was collected before the induction of BCG therapy (pre-BCG blood; both discovery and validation cohorts) and after six doses of BCG (post-BCG blood; only discovery cohort). Metabolome analysis of serum samples was conducted using capillary electrophoresis time-of-flight mass spectrometry. The endpoint was intravesical recurrence-free survival, which was analysed

SUBMITTER: Miyake M 

PROVIDER: S-EPMC11921002 | biostudies-literature | 2025 Jan-Mar

REPOSITORIES: biostudies-literature